{"id":246059,"date":"2012-06-26T13:14:45","date_gmt":"2012-06-26T13:14:45","guid":{"rendered":"http:\/\/www.eugenesis.com\/a-product-and-pipeline-analysis-of-the-u-s-type-2-diabetes-mellitus-market\/"},"modified":"2012-06-26T13:14:45","modified_gmt":"2012-06-26T13:14:45","slug":"a-product-and-pipeline-analysis-of-the-u-s-type-2-diabetes-mellitus-market","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/a-product-and-pipeline-analysis-of-the-u-s-type-2-diabetes-mellitus-market.php","title":{"rendered":"A Product and Pipeline Analysis of the U.S. Type 2 Diabetes Mellitus Market"},"content":{"rendered":"<p><p>    NEW YORK, June 26, 2012 \/PRNewswire\/ -- A Product and Pipeline Analysis of the U.S.    Type 2 Diabetes Mellitus Market  <\/p>\n<p>    <a href=\"http:\/\/www.reportlinker.com\/p0920065\/A-Product-and-Pipeline-Analysis-of-the-US-Type-2-Diabetes-Mellitus-Market.html#utm_source=prnewswire&#038;utm_medium=pr&#038;utm_campaign=Pathology\" rel=\"nofollow\">http:\/\/www.reportlinker.com\/p0920065\/A-Product-and-Pipeline-Analysis-of-the-US-Type-2-Diabetes-Mellitus-Market.html#utm_source=prnewswire&#038;utm_medium=pr&#038;utm_campaign=Pathology<\/a>  <\/p>\n<p>    This research service presents a marketed and pipeline analysis    of the U.S. type 2 diabetes mellitus market. According to the    2011 National Diabetes Fact Sheet, 25.8 million children and    adults (or 8.3 percent of the population) in the United States    suffer from diabetes. Type 2 diabetes mellitus is the most    common form of diabetes; approximately 90 to 95 percent of    diabetes patients suffer from type 2 diabetes mellitus. The    purpose of this study is to highlight the current market    landscape, and provide a competitive analysis of all marketed    and pipeline drugs in development for type 2 diabetes mellitus.    Dashboard slides are provided for all marketed and Phase 3    drugs in development for type 2 diabetes mellitus.  <\/p>\n<p>    2. Introduction  <\/p>\n<p>    Market Overview - Segmentation  <\/p>\n<p>    3. Competitive Landscape  <\/p>\n<p>    Type 2 Diabetes Competitive Landscape - Orals  <\/p>\n<p>    Type 2 Diabetes Competitive Lanscape - Parenterals  <\/p>\n<p>    Product Analysis - Orals  <\/p>\n<p>    Product Analysis - Parenterals  <\/p>\n<\/p>\n<p>Link:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/product-pipeline-analysis-u-type-122200593.html;_ylt=A2KJNF_AtelPumoAncf_wgt.\" title=\"A Product and Pipeline Analysis of the U.S. Type 2 Diabetes Mellitus Market\">A Product and Pipeline Analysis of the U.S. Type 2 Diabetes Mellitus Market<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> NEW YORK, June 26, 2012 \/PRNewswire\/ -- A Product and Pipeline Analysis of the U.S. Type 2 Diabetes Mellitus Market <a href=\"http:\/\/www.reportlinker.com\/p0920065\/A-Product-and-Pipeline-Analysis-of-the-US-Type-2-Diabetes-Mellitus-Market.html#utm_source=prnewswire&#038;utm_medium=pr&#038;utm_campaign=Pathology\" rel=\"nofollow\">http:\/\/www.reportlinker.com\/p0920065\/A-Product-and-Pipeline-Analysis-of-the-US-Type-2-Diabetes-Mellitus-Market.html#utm_source=prnewswire&#038;utm_medium=pr&#038;utm_campaign=Pathology<\/a> This research service presents a marketed and pipeline analysis of the U.S. type 2 diabetes mellitus market <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/a-product-and-pipeline-analysis-of-the-u-s-type-2-diabetes-mellitus-market.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577487],"tags":[],"class_list":["post-246059","post","type-post","status-publish","format-standard","hentry","category-pathology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/246059"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=246059"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/246059\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=246059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=246059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=246059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}